Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies

Abstract

The objective of this study is to identify the effects of statins and risk factors for thrombosis in patients with new onset of systemic lupus erythematosus (SLE) with or without antiphospholipid antibodies (aPL). Consecutive patients with SLE without history of thrombotic events were retrospectively enrolled from April 1997 to February 2014. The development of first thrombosis and death caused by thrombosis were defined as the study endpoint. Risk and protective factors for developing thrombosis were analyzed. A total of 152 patients, 80 positive and 72 negative for aPL, were included. In aPL-positive patients, 15 developed arterial (n = 6) and venous (n = 9) thrombosis (median follow-up period 69 months). Cox’s proportional hazards model showed that older age at SLE onset and IgG-anticardiolipin antibodies (aCL) were statistically significant risks for thrombosis. Statin therapy was identified as a statistically significant protective factor against thrombosis (hazard ratio 0.12, 95% confidence interval 0.01–0.98). In aPL-negative patients (median follow-up period 46 months), seven patients developed thrombosis (five arterial and two venous). No risk factors for thrombosis were found in this group. In aPL-positive patients with SLE, the late disease onset and the presence of IgG-aCL represented additional risk factors for thrombosis. Statin treatment appeared as a protective factor for thrombosis.

Keywords

Systemic lupus erythematosus antiphospholipid antibodies thrombosis statins

Get full access to this article

View all access options for this article.

References

Feldman

Hiraki

Winkelmayer

et al.

Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol 2015; 67: 1577–1585.

Cervera

Khamashta

Font

et al.

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82: 299–308.

Bernatsky

Boivin

Joseph

et al.

Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550–2557.

Mok

Tang

Petri

. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: A comparison of three ethnic groups. Arthritis Rheum 2005; 52: 2774–2782.

Love

Santoro

. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682–698.

Harris

Gharavi

Asherson

Boey

Hughes

. Cerebral infarction in systemic lupus: Association with anticardiolipin antibodies. Clin Exp Rheumatol 1984; 2: 47–51.

Atsumi

Ieko

Bertolaccini

et al.

Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000; 43: 1982–1993.

Miyakis

Lockshin

Atsumi

et al.

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

Calvo-Alén

Toloza

Fernández

et al.

Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum 2005; 52: 2060–2068.

10.

Tektonidou

Laskari

Panagiotakos

Moutsopoulos

. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009; 61: 29–36.

11.

Crowther

Ginsberg

Julian

et al.

A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133–1138.

12.

Finazzi

Marchioli

Brancaccio

et al.

A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848–853.

13.

Garcia

Khamashta

Crowther

. How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: A case-based review. Blood 2007; 110: 3122–3127.

14.

Lim

Crowther

Eikelboom

. Management of antiphospholipid antibody syndrome: A systematic review. JAMA 2006; 295: 1050–1057.

15.

Ruiz-Irastorza

Hunt

Khamashta

. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007; 57: 1487–1495.

16.

Ridker

. JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Rationale and design of the JUPITER trial. Circulation 2003; 108: 2292–2297.

17.

Biere-Rafi

Hutten

Squizzato

et al.

Statin treatment and the risk of recurrent pulmonary embolism. Eur Heart J 2013; 34: 1800–1806.

18.

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357.

19.

Glynn

Danielson

Fonseca

et al.

A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851–1861.

20.

Meroni

Raschi

Testoni

et al.

Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001; 44: 2870–2878.

21.

Ferrara

Swerlick

Casper

et al.

Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2004; 2: 1558–1563.

22.

López-Pedrera

Ruiz-Limón

Aguirre

MÁ

et al.

Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis 2011; 70: 675–682.

23.

Erkan

Aguiar

Andrade

et al.

14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Autoimmun Rev 2014; 13: 685–696.

24.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

25.

Tan

Cohen

Fries

et al.

The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

26.

Gladman

Ibañez

Urowitz

. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288–291.

27.

Brandt

Triplett

Alving

Scharrer

. Criteria for the diagnosis of lupus anticoagulants: An update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185–1190.

28.

Pengo

Tripodi

Reber

et al.

Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737–1740.

29.

Harris

Gharavi

Patel

Hughes

. Evaluation of the anti-cardiolipin antibody test: Report of an international workshop held 4 April 1986. Clin Exp Immunol 1987; 68: 215–222.

30.

Amengual

Atsumi

Khamashta

Koike

Hughes

. Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol 1996; 35: 1239–1243.

31.

Toloza

Uribe

McGwin

Jr et al.

Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004; 50: 3947–3957.

32.

Kaiser

Cleveland

Criswell

. Risk and protective factors for thrombosis in systemic lupus erythematosus: Results from a large, multi-ethnic cohort. Ann Rheum Dis 2009; 68: 238–241.

33.

Cervera

Khamashta

Font

et al.

Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999; 78: 167–175.

34.

Wahl

Guillemin

de Maistre

Perret

Lecompte

Thibaut

. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—a meta-analysis. Lupus 1997; 6: 467–473.

35.

Finazzi

Brancaccio

Moia

et al.

Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530–536.

36.

Sarabi

Chang

Bobba

et al.

Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. Arthritis Rheum 2005; 53: 609–612.

37.

Romero-Díaz

García-Sosa

Sánchez-Guerrero

. Thrombosis in systemic lupus erythematosus and other autoimmune diseases of recent onset. J Rheumatol 2009; 36: 68–75.

38.

Johannesdottir

Horváth-Puhó

Dekkers

et al.

Use of glucocorticoids and risk of venous thromboembolism: A nationwide population-based case-control study. JAMA Intern Med 2013; 173: 743–752.

39.

Wahl

Bounameaux

de Moerloose

Sarasin

. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: Do the benefits outweigh the risks? A decision analysis. Arch Intern Med 2000; 160: 2042–2048.

40.

Erkan

Harrison

Levy

et al.

Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007; 56: 2382–2391.

41.

Ahn

Alarcón

et al.

Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 2005; 44: 1303–1307.

42.

Kwak

Mulhaupt

Myit

Mach

. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399–1402.

43.

Tsai

Cushman

Rosamond

et al.

Coagulation factors, inflammation markers, and venous thromboembolism: The longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002; 113: 636–642.

44.

Undas

Brummel-Ziedins

Mann

. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005; 25: 287–294.

45.

Sen-Banerjee

Mir

Lin

et al.

Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation 2005; 112: 720–726.

46.

Kaba

Francis

Moss

et al.

Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction. J Thromb Haemost 2004; 2: 718–725.

47.

Zhao

Xie

Tian

Zhang

. Efficacy and safety of statins in the prevention of atherosclerosis in patients with systemic lupus erythematosus—a meta-analysis of randomized controlled trials. Int J Cardiol 2013; 167: 301–303.

48.

Ferrara

Liu

Espinola

et al.

Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003; 48: 3272–3279.

49.

Erkan

Willis

Murthy

et al.

A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis 2014; 73: 1176–1180.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB